Tuesday, July 30, 2019 12:35:05 AM
$LAHO ..Global Stem..Market to Reach US$ 467 billion by 2024 ..Due to the increased funding from Government and Private sector and rising global awareness.
https://www.marketwatch.com/press-release/global-stem-cells-market-is-determined-to-reach-us-467-billion-by-2024-2019-03-05
Regenerative medicine will dramatically alter the U.S. healthcare industry
..Because of the economic potential of this industry (the worldwide market for regenerative medicine is conservatively estimated to be $500 billion..
An example of some conditions and diseases that could be easily cured by regenerative medicine and their current cost of treatmentt include:
250,000 patients receive heart valves, at a cost of $27 billion annually
950,000 people die of heart disease or stroke, at a cost of $351 billion annually(8)
17 million patients with diabetes, at a cost of $132 billion annually
..By doing so, we can make tissue and organ failure a relic of the past by 2020.
Interagency Federal Working Group on Regenerative Medicine
Chair
Howard Zucker, MD, JD
Deputy Assistant Secretary for Health
U.S. Department of Health and Human Services
National Institutes of Health
Donna Dean, PhD
Colleen Guay-Broder, MPH
Eleni Kousvelari, PhD
Christine Kelley, PhD
John Watson, PhD
Josh Zimmerberg, PhD
Food and Drug Administration
Charles Durfor, PhD
Donald Fink, PhD
Joyce Frey, PhD
Jesse Goodman, MD
Darin Weber, PhD
Celia Witten, PhD
http://singularity-2045.org/HHS-regenerative-medicine-2020-vision-archive-2014.html
Adimarket 119 pages Medical devices!
https://2nvdue1pi3s51uaik42s7kgz-wpengine.netdna-ssl.com/wp-content/uploads/2017/05/ADIMarket_1.pdf
Studies a U.S. FDA-regulated Device Product: YES
Estimated Study Start Date : May 13, 2019
Estimated Primary Completion Date : September 15, 2020
Estimated Study Completion Date : November 1, 2020
https://clinicaltrials.gov/ct2/show/NCT03752827
Pending Institutional Review Board (IRB) approval, Global Stem Cells Group, Inc. has announced plans to conduct a multi-centre, placebo controlled clinical trial to measure the safety and effectiveness of the intra-articular application of freshly isolated bone marrow stem cells for the treatment of osteoarthritis.
https://biovaultfamily.com/health-hub/musculoskeletal-conditions/global-stem-cells-group-plans-bone-marrow-clinical-trials-for-knee-osteoarthritis/
https://www.prunderground.com/global-stem-cells-group-takes-part-in-clinical-trial/00150836/
$LAHO
https://www.marketwatch.com/press-release/global-stem-cells-market-is-determined-to-reach-us-467-billion-by-2024-2019-03-05
Regenerative medicine will dramatically alter the U.S. healthcare industry
..Because of the economic potential of this industry (the worldwide market for regenerative medicine is conservatively estimated to be $500 billion..
An example of some conditions and diseases that could be easily cured by regenerative medicine and their current cost of treatmentt include:
250,000 patients receive heart valves, at a cost of $27 billion annually
950,000 people die of heart disease or stroke, at a cost of $351 billion annually(8)
17 million patients with diabetes, at a cost of $132 billion annually
..By doing so, we can make tissue and organ failure a relic of the past by 2020.
Interagency Federal Working Group on Regenerative Medicine
Chair
Howard Zucker, MD, JD
Deputy Assistant Secretary for Health
U.S. Department of Health and Human Services
National Institutes of Health
Donna Dean, PhD
Colleen Guay-Broder, MPH
Eleni Kousvelari, PhD
Christine Kelley, PhD
John Watson, PhD
Josh Zimmerberg, PhD
Food and Drug Administration
Charles Durfor, PhD
Donald Fink, PhD
Joyce Frey, PhD
Jesse Goodman, MD
Darin Weber, PhD
Celia Witten, PhD
http://singularity-2045.org/HHS-regenerative-medicine-2020-vision-archive-2014.html
Adimarket 119 pages Medical devices!
https://2nvdue1pi3s51uaik42s7kgz-wpengine.netdna-ssl.com/wp-content/uploads/2017/05/ADIMarket_1.pdf
Studies a U.S. FDA-regulated Device Product: YES
Estimated Study Start Date : May 13, 2019
Estimated Primary Completion Date : September 15, 2020
Estimated Study Completion Date : November 1, 2020
https://clinicaltrials.gov/ct2/show/NCT03752827
Pending Institutional Review Board (IRB) approval, Global Stem Cells Group, Inc. has announced plans to conduct a multi-centre, placebo controlled clinical trial to measure the safety and effectiveness of the intra-articular application of freshly isolated bone marrow stem cells for the treatment of osteoarthritis.
https://biovaultfamily.com/health-hub/musculoskeletal-conditions/global-stem-cells-group-plans-bone-marrow-clinical-trials-for-knee-osteoarthritis/
https://www.prunderground.com/global-stem-cells-group-takes-part-in-clinical-trial/00150836/
$LAHO
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
